文献速递神经肿瘤

地塞米松诱导的白细胞增多与新诊断胶质母细胞瘤不良生存相关

Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma.
PubMed 文献 · J Neurooncol · 2018-01-18

该回顾性研究分析了113例新诊断胶质母细胞瘤患者,发现年龄是地塞米松诱导的白细胞增多的危险因素(p<0.05)。地塞米松诱导的白细胞增多降低总生存期(HR 2.25,95%CI [1.15-4.38],p<0.001)和无进展生存期(HR 2.23,95%CI [1.09-4.59],p<0.01),且患者肿瘤CD15+粒细胞和CD3+淋巴细胞浸润显著减少(均p<0.05)。作者建议对出现地塞米松诱导的白细胞增多的患者考虑限制剂量或使用其他减轻水肿的药物。

要点

  • 年龄是地塞米松诱导的白细胞增多的危险因素(p<0.05)。
  • 地塞米松诱导的白细胞增多与总生存期(HR 2.25)和无进展生存期(HR 2.23)降低相关。
  • 地塞米松诱导的白细胞增多患者肿瘤CD15+粒细胞和CD3+淋巴细胞浸润显著减少。

核心结论

  • 地塞米松诱导的白细胞增多与新诊断胶质母细胞瘤患者不良生存相关,作者建议对此类患者考虑限制剂量或使用其他减轻水肿的药物。

研究设计与样本

  • 回顾性分析113例新诊断胶质母细胞瘤患者,并对可用组织切片进行粒细胞和淋巴细胞肿瘤浸润的免疫组化分析。

主要发现

  • 年龄是地塞米松诱导的白细胞增多的危险因素(p<0.05)。
  • 地塞米松诱导的白细胞增多降低总生存期(HR 2.25,95%CI [1.15-4.38],p<0.001)和无进展生存期(HR 2.23,95%CI [1.09-4.59],p<0.01)。
  • 地塞米松诱导的白细胞增多患者CD15+粒细胞(p<0.05)和CD3+淋巴细胞(p<0.05)肿瘤浸润显著减少。

临床怎么用

  • 作者建议,对出现地塞米松诱导的白细胞增多的患者,应考虑限制剂量或使用其他减轻水肿的药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite its well-characterized side effects, dexamethasone is widely used in the pre-, peri- and postoperative neurosurgical setting due to its effective relief of tumor-induced symptoms through the reduction of tumor-associated edema. However, some patients show laboratory-defined dexamethasone induced elevation of white blood cell count, and its impact on glioblastoma progression is unknown. We retrospectively analyzed 113 patients with newly diagnosed glioblastoma to describe the incidence, risk factors and clinical features of dexamethasone-induced leukocytosis in primary glioblastoma patients. We further conducted an immunohistochemical analysis of the granulocyte and lymphocyte tumor-infiltration in the available corresponding histological sections. Patient age was identified to be a risk factor for the development of dexamethasone-induced leukocytosis (p < 0.05). The presence of dexamethasone-induced leukocytosis decreased overall survival (HR 2.25 95% CI [1.15-4.38]; p < 0.001) and progression-free survival (HR 2.23 95% CI [1.09-4.59]; p < 0.01). Furthermore, patients with dexamethasone-induced leukocytosis had significantly reduced CD15 + granulocytic- (p < 0.05) and CD3 + lymphocytic tumour infiltration (p < 0.05). We identified a subgroup of glioblastoma patients that are at particularly high risk for poor outcome upon dexamethasone treatment. Therefore, restrictive dosage or other edema reducing substances should be considered in patients with dexamethasone-induced leukocytosis.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Dubinski D, Won SY, Gessler F, et al. Dexamethasone-induced leukocytosis is associated with poor survival in newly diagnosed glioblastoma. J Neurooncol. 2018. PMID: 29349612. doi:10.1007/s11060-018-2761-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。